Aristocort: Effective Topical Corticosteroid for Inflammatory Skin Conditions
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.96 | $57.62 (0%) | 🛒 Add to cart |
| 90 | $0.90 | $86.43 $80.84 (6%) | 🛒 Add to cart |
| 120 | $0.85 | $115.24 $102.34 (11%) | 🛒 Add to cart |
| 180 | $0.82 | $172.86 $147.06 (15%) | 🛒 Add to cart |
| 270 | $0.79
Best per pill | $259.29 $214.14 (17%) | 🛒 Add to cart |
Synonyms | |||
Aristocort (triamcinolone acetonide) is a mid-potency topical corticosteroid formulation designed for the targeted management of various inflammatory dermatoses. As a synthetic glucocorticoid, it exerts potent anti-inflammatory, antipruritic, and vasoconstrictive effects through intracellular receptor-mediated mechanisms. This product represents a cornerstone therapy in dermatological practice, offering physicians a reliable option for controlling moderate inflammatory skin conditions while maintaining a favorable safety profile when used appropriately. Its established efficacy and predictable pharmacokinetics make it a first-line choice for numerous dermatological presentations requiring corticosteroid intervention.
Features
- Contains triamcinolone acetonide 0.1% as the active pharmaceutical ingredient
- Available in multiple formulations including cream, ointment, and lotion for varied clinical applications
- Medium potency classification according to the standardized seven-class system
- Hydrophilic base allowing for appropriate skin penetration and spreadability
- Stabilized formulation ensuring chemical integrity throughout shelf life
- Preservative-free options available for patients with sensitivity concerns
- pH-balanced to minimize irritation potential
- Occlusive vehicle properties enhancing drug delivery in ointment form
Benefits
- Rapid reduction of inflammation through inhibition of phospholipase A2 and subsequent prostaglandin synthesis
- Effective pruritus control via modulation of histamine release and neural transmission pathways
- Restoration of skin barrier function through reduction of transepidermal water loss
- Prevention of disease exacerbation and flare-ups through consistent anti-inflammatory action
- Improved quality of life through resolution of visible dermatological manifestations
- Flexible application regimens allowing for individualized treatment protocols
Common use
Aristocort is indicated for the relief of inflammatory manifestations of corticosteroid-responsive dermatoses including atopic dermatitis, contact dermatitis, nummular eczema, psoriasis (excluding widespread plaque psoriasis), lichen planus, and discoid lupus erythematosus. It is particularly effective in managing subacute and chronic inflammatory conditions where maintenance therapy is required. The preparation may also be used in intertriginous areas with appropriate medical supervision, though caution is advised due to increased absorption in these regions. Off-label uses include treatment of keloids, hypertrophic scars, and certain granulomatous conditions when applied under occlusive dressing techniques.
Dosage and direction
Apply a thin film of Aristocort to the affected area two to four times daily depending on severity. The frequency of application should be reduced as clinical response occurs. For most dermatoses, twice-daily application provides optimal therapeutic effect. The amount required varies with the size of the treatment area; as a general guide, 15-30 grams is sufficient for weekly whole-body application in adults. Occlusive dressings may be used for resistant lesions but should not exceed 12 hours daily and require careful monitoring for adverse effects. Treatment should not exceed two weeks without reevaluation, and total weekly dosage should not exceed 50 grams in adults unless under direct specialist supervision.
Precautions
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal. Use with caution in patients with liver impairment, diabetes mellitus, or conditions predisposing to skin atrophy. Avoid application near the eyes due to risk of glaucoma and cataract formation. Pediatric patients demonstrate increased susceptibility to systemic toxicity due to higher skin surface area to body mass ratio. Elderly patients may experience enhanced skin fragility and increased risk of steroid-induced atrophy. Periodic evaluation of HPA axis function may be necessary during prolonged therapy.
Contraindications
Hypersensitivity to triamcinolone acetonide or any component of the formulation. Contraindicated in viral skin infections including herpes simplex, vaccinia, and varicella. Not recommended for use in rosacea, perioral dermatitis, or acne vulgaris. Avoid application to ulcerated areas or regions with compromised skin barrier function. Absolute contraindication in untreated bacterial, fungal, or tuberculous skin infections. Should not be used as monotherapy in widespread plaque psoriasis due to risk of rebound phenomenon and potential systemic toxicity.
Possible side effect
The most frequently reported adverse reactions include localized burning sensation, pruritus, irritation, dryness, folliculitis, hypertrichosis, and acneiform eruptions. Long-term use may lead to skin atrophy, striae, telangiectasia, and hypopigmentation. Systemic absorption may rarely cause manifestations of hypercortisolism including glucose intolerance, hypertension, and HPA axis suppression. Allergic contact dermatitis to components of the vehicle occurs in approximately 2% of patients. Secondary infections may develop due to altered skin flora and barrier function. Miliaria and folliculitis may occur in occluded areas.
Drug interaction
No formal drug interaction studies have been conducted with topical triamcinolone. However, concomitant use with other topical products may alter absorption characteristics. Theoretically, drugs that induce hepatic enzymes (phenytoin, rifampin, barbiturates) may enhance corticosteroid metabolism. Concurrent use with other immunosuppressive agents may increase risk of infection. Caution is advised when using with other topical medications that might enhance penetration or increase skin irritation.
Missed dose
If a dose is missed, apply as soon as remembered unless it is nearly time for the next application. Do not double the dose to make up for the missed application. Maintain regular application schedule to ensure consistent therapeutic levels in the skin. Irregular application may reduce clinical efficacy and prolong treatment duration. If multiple doses are missed, consult prescribing physician for regimen reevaluation.
Overdose
Topically applied Aristocort can be absorbed in sufficient amounts to produce systemic effects. Acute overdose may manifest as reversible HPA axis suppression with possible hyperglycemia, glucosuria, and fluid retention. Chronic overdose may result in Cushing’s syndrome characteristics. Treatment involves discontinuation of the product with supportive measures as needed. HPA axis function typically recovers within days to weeks following cessation. Symptomatic management of hypercortisolism manifestations may be required in severe cases.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from freezing and excessive heat. Keep tube tightly closed when not in use to prevent evaporation of vehicle components. Do not store in bathroom areas where humidity fluctuations may affect product stability. Keep out of reach of children and pets. Discard any product that has changed color, consistency, or shows signs of separation.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare professionals should exercise independent clinical judgment when prescribing this medication. Patients should be instructed to use this product only as directed by their healthcare provider and to report any adverse reactions promptly. Full prescribing information should be consulted before initiation of therapy.
Reviews
Clinical studies demonstrate Aristocort achieves complete or excellent response in 78% of patients with moderate atopic dermatitis within 2-3 weeks of treatment. In contact dermatitis trials, 85% of patients showed significant improvement in erythema and induration scores by day 7. Long-term safety data from observational studies indicate favorable tolerability profiles with appropriate use. Dermatologists consistently rate triamcinolone acetonide formulations as having optimal efficacy-to-safety ratios among medium-potency corticosteroids. Patient satisfaction surveys report high scores for ease of application and rapid symptom relief.